Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230603 | 0.81 | TP53 (0.39) | EGFRCSF1R | |
| SCHEMBL5231179 | 0.81 | TP53 (0.39) | EGFRCSF1R | |
| SCHEMBL7529108 | 0.81 | TP53 (0.39) | EGFRCSF1R | |
| SCHEMBL5228380 | 0.81 | TP53 (0.39) | EGFRCSF1R | |
| SCHEMBL7674150 | 0.80 | LCK (0.39) | EGFRCSF1R | |
| SCHEMBL5234743 | 0.79 | TP53 (0.40) | — | |
| SCHEMBL5230287 | 0.79 | TP53 (0.42) | EGFRCSF1R | |
| SCHEMBL5230299 | 0.78 | TP53 (0.42) | EGFRCSF1R | |
| SCHEMBL5228166 | 0.77 | TP53 (0.37) | EGFRCSF1R | |
| SCHEMBL5232944 | 0.76 | MAPK14 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-6451804-B1 | Heteroalkylamino-substituted bicyclic nitrogen heterocycles | SYNTEX (U.S.A.) LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1228070-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |